Silver Book Fact

A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to control different cells at specific times.

Gradinaru, Viviana, Murtaza Mogri, Kimberly R. Thompson, Jaimie M. Henderson, and Karl Deisseroth. Optical Deconstruction of Parkinsonian Neural Circuitry. Science. 2009; 324(5925): 354-9. http://www.ncbi.nlm.nih.gov/pubmed/19299587

Reference

Title
Optical Deconstruction of Parkinsonian Neural Circuitry
Publication
Science
Publication Date
2009
Authors
Gradinaru, Viviana, Murtaza Mogri, Kimberly R. Thompson, Jaimie M. Henderson, and Karl Deisseroth
Volume & Issue
Volume 324, Issue 5925
Pages
354-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.  
  • A $1 billion-investment in Alzheimer’s research that led to research breakthroughs by 2010 could have a 10-to-1 return by 2015, and a 90-to-1 return by 2050.  
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient…